JMP Securities Reiterates Market Outperform on CureVac, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating on CureVac (NASDAQ:CVAC) and maintained a price target of $18.
July 03, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating on CureVac and maintained a price target of $18.
The reiteration of a Market Outperform rating and the maintenance of a price target at $18 by a reputable analyst can boost investor confidence in CureVac, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100